Multidisciplinary Management of Head and Neck Cancer

Head and neck cancer is a very common cancer worldwide with an estimated 500,000 individuals diagnosed each year. In the United States an average of 39,000 new cases are reported each year representing between 3 to 5% of all new cancer cases diagnosed annually. Head and neck cancers are more common in men and in individuals over the age of 50.
The treatment of head and neck cancer is extremely challenging and involves insight and expertise from multiple disciplines. Multidisciplinary Management of Head and Neck Cancer is a comprehensive textbook looking at different aspects of head and neck cancer, including the diagnosis, treatment and outcomes for patients with this disease. The chapters written by world-renowned experts cover the entire discipline of head and neck oncology and include discussion of the role of HPV infections, advances in radiotherapy, new surgical techniques, novel agents in thyroid therapy and more. The book is designed to be both practical and comprehensive for the physicians treating this complex disease.

Features of Multidisciplinary Management of Head and Neck Cancer include:

A chapter on the role of HPV infections in head and neck cancer
A chapter on new advances in radiotherapy for head and neck cancer, including review IMRT, new standards and potential pitfalls
Detailed discussion of the role of chemotherapy in head and neck cancer, including commonly used drugs and how to combine them with radiotherapy to improve patient outcomes
Detailed discussion on incorporating novel agents with radiotherapy
Detailed discussion of novel therapeutics in head and neck cancer, including new drugs and biologics
- return to top -
Contents
1. Role of HPV infections in head and neck cancer; 2.New advances in radiotherapy for head and neck cancer; 3. Molecularly Targeted Agents in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck; 4. Induction chemotherapy in locally advanced head and neck cancer: an evolving concept; 5. New surgical techniques in head and neck cancer; 6. Incorporating novel agents with chemotherapy and radiotherapy for the treatment of locally advanced squamous cel carcinoma of the head and neck; 7. Concurrent chemoradiotherapy in head and neck cancer; 8. Novel agents in thyroid cancer; 9. Prevention and treatment of dysphagia and aspiration in head and neck cancer; 10. Functional imaging of the head and neck with positron emission tomography (PET); 11. Diagnostic and therapeutic advances in multidisciplinary care for nasopharyngeal cancer
- return to top -

About the Author
Robert Haddad, MD
is Clinical Director, Head and Neck Oncology, Dana Farber Cancer Institute, Harvard Medical School.